➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
McKinsey
Boehringer Ingelheim
Dow

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

SINEMET CR Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Sinemet Cr, and what generic alternatives are available?

Sinemet Cr is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in SINEMET CR is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

Drug patent expirations by year for SINEMET CR
Recent Clinical Trials for SINEMET CR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Western University, CanadaN/A
New York State Psychiatric InstitutePhase 4
Columbia UniversityPhase 4

See all SINEMET CR clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for SINEMET CR
Paragraph IV (Patent) Challenges for SINEMET CR
Tradename Dosage Ingredient NDA Submissiondate
SINEMET CR TABLET, EXTENDED RELEASE;ORAL carbidopa; levodopa 019856

US Patents and Regulatory Information for SINEMET CR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme SINEMET CR carbidopa; levodopa TABLET, EXTENDED RELEASE;ORAL 019856-002 Dec 24, 1992 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Merck Sharp Dohme SINEMET CR carbidopa; levodopa TABLET, EXTENDED RELEASE;ORAL 019856-001 May 30, 1991 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SINEMET CR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme SINEMET CR carbidopa; levodopa TABLET, EXTENDED RELEASE;ORAL 019856-001 May 30, 1991 ⤷  Free Forever Trial ⤷  Free Forever Trial
Merck Sharp Dohme SINEMET CR carbidopa; levodopa TABLET, EXTENDED RELEASE;ORAL 019856-002 Dec 24, 1992 ⤷  Free Forever Trial ⤷  Free Forever Trial
Merck Sharp Dohme SINEMET CR carbidopa; levodopa TABLET, EXTENDED RELEASE;ORAL 019856-001 May 30, 1991 ⤷  Free Forever Trial ⤷  Free Forever Trial
Merck Sharp Dohme SINEMET CR carbidopa; levodopa TABLET, EXTENDED RELEASE;ORAL 019856-001 May 30, 1991 ⤷  Free Forever Trial ⤷  Free Forever Trial
Merck Sharp Dohme SINEMET CR carbidopa; levodopa TABLET, EXTENDED RELEASE;ORAL 019856-002 Dec 24, 1992 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
McKinsey
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.